CRIS Current Research Information System

POTENA, LUCIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.436
AS - Asia 6.131
EU - Europa 4.625
SA - Sud America 349
AF - Africa 320
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 4
Totale 17.889
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.336
SG - Singapore 1.669
VN - Vietnam 1.649
CN - Cina 1.508
IT - Italia 1.187
GB - Regno Unito 824
DE - Germania 615
SE - Svezia 571
HK - Hong Kong 396
FR - Francia 276
BR - Brasile 259
IN - India 255
UA - Ucraina 236
RU - Federazione Russa 190
IE - Irlanda 167
NL - Olanda 158
KR - Corea 136
JP - Giappone 121
FI - Finlandia 97
ZA - Sudafrica 92
BD - Bangladesh 90
TG - Togo 72
JO - Giordania 64
CA - Canada 63
CI - Costa d'Avorio 63
BG - Bulgaria 59
EE - Estonia 49
AT - Austria 44
PH - Filippine 43
AR - Argentina 41
CH - Svizzera 38
TH - Thailandia 34
NG - Nigeria 31
SC - Seychelles 31
ES - Italia 23
TR - Turchia 22
AU - Australia 21
BE - Belgio 21
ID - Indonesia 20
MX - Messico 20
IQ - Iraq 19
IR - Iran 19
PL - Polonia 17
TW - Taiwan 16
PK - Pakistan 15
CO - Colombia 11
LT - Lituania 11
SA - Arabia Saudita 11
EC - Ecuador 10
GR - Grecia 10
UZ - Uzbekistan 9
AE - Emirati Arabi Uniti 7
MA - Marocco 7
PY - Paraguay 7
DZ - Algeria 6
LB - Libano 6
PT - Portogallo 6
UY - Uruguay 6
VE - Venezuela 6
AZ - Azerbaigian 5
CL - Cile 5
RO - Romania 5
TN - Tunisia 5
CZ - Repubblica Ceca 4
DK - Danimarca 4
EU - Europa 4
KE - Kenya 4
PE - Perù 4
SI - Slovenia 4
CR - Costa Rica 3
EG - Egitto 3
HU - Ungheria 3
MY - Malesia 3
TT - Trinidad e Tobago 3
AM - Armenia 2
BB - Barbados 2
CY - Cipro 2
FJ - Figi 2
JM - Giamaica 2
KG - Kirghizistan 2
NI - Nicaragua 2
SV - El Salvador 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
ET - Etiopia 1
GE - Georgia 1
GH - Ghana 1
KH - Cambogia 1
KZ - Kazakistan 1
LY - Libia 1
MC - Monaco 1
MU - Mauritius 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
PR - Porto Rico 1
PS - Palestinian Territory 1
RS - Serbia 1
Totale 17.883
Salva come PNG Salva come JPEG
Città #
Singapore 1.183
Ashburn 755
Southend 682
Fairfield 465
San Jose 461
Chandler 413
Houston 407
Ho Chi Minh City 386
Hong Kong 380
Hanoi 364
Hefei 293
Santa Clara 260
Woodbridge 249
Wilmington 231
Seattle 221
Bologna 215
Beijing 209
Princeton 197
Boardman 175
Cambridge 171
Dublin 167
Jacksonville 154
Ann Arbor 136
New York 124
Los Angeles 120
Seoul 116
Lauterbourg 108
Tokyo 104
Milan 102
Council Bluffs 90
Bremen 85
Westminster 74
Helsinki 73
Lomé 72
Nanjing 70
Padova 70
Dong Ket 69
Amman 64
Buffalo 64
Abidjan 63
Berlin 63
Munich 63
Da Nang 61
Dallas 60
Haiphong 58
Sofia 58
Turin 58
Rome 54
Frankfurt am Main 50
Shenyang 44
São Paulo 44
Jinan 42
Mülheim 34
Medford 33
Shanghai 33
Bengaluru 32
Redmond 32
Saint Petersburg 32
Florence 31
Abeokuta 29
Changsha 29
Guangzhou 28
Hebei 28
Redondo Beach 28
Vienna 28
Johannesburg 25
Bern 24
Falkenstein 24
Hải Dương 24
San Diego 24
Biên Hòa 23
London 23
Tianjin 22
Zhengzhou 22
Nanchang 21
Toronto 21
Jiaxing 20
Phoenix 19
Brussels 18
Orem 18
Turku 18
Mahé 17
Chicago 16
The Dalles 16
Yubileyny 16
Bangkok 15
Bắc Ninh 15
Stockholm 15
Thái Nguyên 15
Verona 15
Amsterdam 14
Can Tho 14
Dearborn 14
Des Moines 14
Ha Long 14
Nuremberg 14
Warsaw 14
Xi'an 14
Brooklyn 13
Olalla 13
Totale 11.318
Salva come PNG Salva come JPEG
Nome #
L'inibitore endogeno della eNOS , la dimetil-arginina simmetrica (ADMA), è un nuovo fattore di rischio di vasculopatia coronarica post trapianto di cuore ed è infulenzato dalla terapia con sirolimus. 428
Impaired dendritic cell immunophenotype and function in heart transplant patients undergoing active cytomegalovirus infection. 371
Evaluation of the Kinetics of Antibody Response to COVID-19 Vaccine in Solid Organ Transplant Recipients: The Prospective Multicenter ORCHESTRA Cohort 328
Relationship between immune response to SARS-CoV2 vaccines and development of breakthrough infection in solid organ transplant recipients: the CONTRAST cohort 254
Changes in exercise capacity induced by heart transplantation: prognostic and therapeutic implications. 251
Clinical relevance of the International Society for Heart and Lung Transplantation consensus classification of primary graft dysfunction after heart transplantation: Epidemiology, risk factors, and outcomes 244
Prognostic stratification and treatment of cardiac light chain amyloidosis: a narrow path in the jungle. 239
Occurrence of Fatal and Nonfatal Adverse Outcomes after Heart Transplantation in Patients with Pretransplant Noncytotoxic HLA Antibodies 227
Heart Transplant and Hepato-Renal Dysfunction: The Model of End-Stage Liver Disease Excluding International Normalized Ratio as a Predictor of Postoperative Outcomes 213
Le complicanze metaboliche post-trapianto di cuore ruolo dell'adiponectina ed associazione con la malattia coronarica del graft 204
New pathological insights into cardiac amyloidosis: implications for non-invasive diagnosis. 204
Identification of TTR-Related Subclinical Amyloidosis With 99mTc-DPD Scintigraphy 203
Monitoring of CMV-specific cell-mediated immunity in heart transplant recipients: clinical utility of the QuantiFERON®-CMV assay for the management of post-transplant CMV infection 202
Manifestations of health anxiety in patients with heart transplant 196
Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure. 195
Age and heart transplantation: results from a heart failure management unit. 195
Diagnosi non invasiva di rigetto miocardico acuto: l'analisi armonica dell'ecg coadiuva la valutazione clinica 193
Correlations Between Cardiac Magnetic Resonance and Myocardial Histologic Findings in Fabry Disease 187
Ischemic injury activates PTHrP and PTH1R expression in human ventricular cardiomyocytes. 186
Long-term safety and effectiveness of statins for heart transplant recipients in routine clinical practice. 185
Safety and efficacy of early aggressive versus cholesterol-driven lipid-lowering strategies in heart transplantation: A pilot, randomized, intravascular ultrasound study. 185
Static and dynamic predictors of adverse events in patients with intermediate cardiopulmonary capacity referred for heart transplantation. 185
Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: Long-term follow-up of the SHIRAKISS randomized, prospective study. 184
Relationship between psychiatric disorders and physical status during the course of a heart transplantation program: a prospective, longitudinal study. 183
Implications of cardiac resynchronization therapy and prophylactic defibrillator implantation among patients eligible for heart transplantation 180
Candidacy for heart transplantation in adult congenital heart disease patients: A cohort study 179
Prognostic stratification of women with chronic heart failure referred for heart transplantation: relevance of gender as compared with gender-related characteristics. 179
Influence of the MELD-XI (Model of End-Stage Liver Disease Excluding INR) on Heart Transplant Outcomes 179
Impact of Pre-Transplant Pulmonary Hypertension Grading on Early- to Long-Term Hemodynamics, Right Venticular Graft Function and Survival After Heart Transplantation 179
Differential effect of everolimus on progression of early and late cardiac allograft vasculopathy in current clinical practice. 178
Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction 177
Clinical and Prognostic Correlates of pAMR Grading in Patients with Suspect Antibody Mediated Rejection 174
Comprehensive Non-invasive Versus Invasive Approach to Evaluate Cardiac Allograft Vasculopathy in Heart Transplantation: The CCTA-HTx Study 173
Differential Effects of Everolimus on Early vs. Late Allograft Vasculopathy Progression in Heart Transplant Recipients: a Longitudinal IVUS-Based Study 173
Qualità della vita e parametri clinico-strumentali nello scompenso cardiaco. 172
Differences in cardiac phenotype and natural history of laminopathies with and without neuromuscular onset 171
EVEROLIMUS REDUCES CAV PROGRESSION AS COMPARED WITH AZATHIOPRINE AND MYCOPHENOLATE: A LONGITUDINAL IVUS- BASED STUDY 170
Hydroxymethyl-glutaryl coenzyme a reductase inhibition limits cytomegalovirus infection in human endothelial cells. 170
Nitrates and Angina: an insight into arterial and venular involvement in blood flow regulation. 169
Clinical presentations leading to arrhythmogenic left ventricular cardiomyopathy 166
Ruolo dell'NT-proBNP nella stratificazione prognostica dei pazienti con scompenso cardiaco cronico. 165
Cyclosporine lowering with everolimus or mycophenolate to preserve renal function in heart recipients: a randomized study. 164
Il rallentamento del flusso di perfusione coronarica valutato con il TIMI frame count è in grado di predire la mortalità a lungo termine nei pazienti con trapianto di cuore 163
Interplay of coronary angiography and intravascular ultrasound in predicting long-term outcomes after heart transplantation 162
Prophylaxis vs. Pre-Emptive Strategies in Preventing Cytomegalovirus-Dependent Cardiac Allograft Vasculopathy 161
Prophylaxis versus preemptive therapy for prevention of the consequences of cytomegalovirus infection in transplant recipients: a still unresolved issue 161
Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients 161
La progressione della coronarografia del graft è proporzionale alla severità dell'infezione da citomegalovirus nei pazienti con trapianto cardiaco. 159
Efficacia e sicurezza dell'ezetimibe in associazione con basse dosi di simvastatina per il trattamento dell'iperlipidemia post-trapianto cardiaco 159
Identification and classification of acute cardiac rejection by intragraft transcriptional profiling. 156
Reproducibility of IVUS Measurements in Heart Transplant Recipients: Increased Quality of Data by Using Dedicated Software for Image Analysis 156
Predicting Right Ventricular Failure in the Current Continuous Flow Left Ventricular Assist Device Era 155
Viral genome search in myocardium of patients with fulminant myocarditis 154
PRE-TRANSPLANT NON-CYTOTOXIC ANTI-HLA ANTIBODIES PREDICT MULTIPLE ADVERSE EVENTS AFTER HEART TRANSPLANTATION 153
Homocysteine-lowering therapy and early progression of transplant vasculopathy: a prospective, randomized, IVUS-based study. 153
Prolactin Inhibition to Treat Postpartum Arrhythmic Storm 152
Using machine learning to predict antibody response to SARS-CoV-2 vaccination in solid organ transplant recipients: the multicentre ORCHESTRA cohort 152
Differential Effect of Everolimus and Metabolic Risk Factors on Early vs. Late Progression of Allograft Vasculopathy: Dissecting Two Faces of the Same Disease 152
Pre-Transplant Non-Cytotoxic Anti-HLA Antibodies Predict Multiple Adverse Events after Heart Transplantation 152
L'inibitore endogeno della eNOS favorisce la progressione dell'infezione da cytoomegalovirus e del rigetto miocardico acuto nei pazienti con trapianto di cuore. 151
Correlazione tra metodi semiquantitativi e quantitativi nella valutazione dell'insufficienza mitralica organica ed associazione con test da sforzo cardiopolmonare e pro-BNP 151
L'infezione da citomegalovirus e i parametri indicativi di insulino-resistenza influenzano in modo distinto e specifico le variazioni nella geometria coronarica nel primo anno dopo trapianto di cuore 149
Does therapeutic drug monitoring (TDM) of trough concentrations suffice for optimizing preemptive therapy with ganciclovir of cytomegalovirus infections in non-renal solid organ transplant recipients? 148
Heart transplantation in hypertrophic cardiomyopathy. 148
Everolimus in kidney transplant recipients at high cardiovascular risk: a narrative review 147
Interplay between Pulmonary Hypertension and Donor-Recipient Matching in the Risk for Early Graft Failure after Heart Transplantation 145
Relevance of cardioverter defibrillators for the prevention of sudden cardiac death on the timing of heart transplantation. 145
Clinical profile and in-hospital outcome of patients supported by intra-aortic balloon pump in the clinical setting of cardiogenic shock 143
Late Changes in Maximal Intimal Thickness after Heart Transplant: Prognostic Implications and Risk Factors 143
Long-term immune response after SARS-CoV2 vaccination in solid organ transplant recipients 142
Prevalence of substance-related disorders in heart transplantation candidates 142
Coronary allograft vasculopathy: pathophysiological interaction between the immune system, infections and metabolic syndrome 139
Psychological predictors of mortality in heart transplanted patients: a prospective, 6-year follow-up study. 139
SAFETY AND EFFICACY OF TWO TYPES OF INFLUENZA VACCINATION IN HEART TRANSPLANT RECIPIENTS: A PROSPECTIVE RANDOMISED CONTROLLED STUDY 138
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians 138
Insufficienza mitralica organica: parametri ecocardiografici, funzionali e neuro-ormonali potenziali predittori di intervento chirurgico a breve termine 136
Extracorporeal Membrane Oxygenation Support System as Bridge to Solution in Refractory Cardiogenic Shock 135
L'infezione subclinica da citomegalovirus modula l'infiammazione sistemica e il rimodellamento coronarico ad un anno dal trapianto. 135
Impact of Current Donor Scores Calculation on Heart Transplantation Outcomes 135
Effect of a Fourth Dose of mRNA Vaccine and of Immunosuppression in Preventing SARS-CoV-2 Breakthrough Infections in Heart Transplant Patients 134
Fulminant Versus Acute Nonfulminant Myocarditis in Patients With Left Ventricular Systolic Dysfunction 134
Potential of medical treatment, device therapy, and conventional surgery in patients referred for heart transplantation. 133
Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions. 130
Impact of prior sternotomy on survival and allograft function after heart transplantation: A single center matched analysis 129
Safety and efficacy of ezetimibe with low doses of simvastatin in heart transplant recipients. 128
Cytomegalovirus infectious burden is proportional to cardiac allograft vasculopathy in heart transplant recipients 128
Studio prospettico randomizzato sull'effetto della terapia con acido folico nella preenzione della malattia coronarica nel paziente trapiantato 122
Donor-derived human herpesvirus 8 infection with Kaposi sarcoma and Kaposi sarcoma inflammatory cytokine syndrome in a heart transplant recipient: A case report 122
Role of Donor-Recipient Match in Determining the Risk for Primary Graft Failure after Heart Transplantation 120
Extracorporeal membrane oxygenation for the treatment of refractory cardiogenic shock in adults: strategies, results, and predictors of mortality = Sistemi di ossigenazione a membrana extracorporea come trattamento per lo shock cardiogeno refrattario nella popolazione adulta: strategie, risultati e predittori di mortalità 120
Donor risk analysis and validation in heart transplants: A single-centre experience 120
COVID-19 in Heart Transplant Recipients: A Multicenter Analysis of the Northern Italian Outbreak 118
Impact of Predicted Heart Mass–Based Donor-Recipient Size Matching on Transplant Outcomes 114
Long-term effect of folic Acid therapy in heart transplant recipients: follow-up analysis of a randomized study. 113
CTA-Derived Pericoronary Fat Attenuation Index Predicts Allograft Rejection and Cardiovascular Events in Heart Transplant Recipients 112
Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. 112
Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis 111
Multicenter Prospective Study for Laboratory Diagnosis of HHV8 Infection in Solid Organ Donors and Transplant Recipients and Evaluation of the Clinical Impact After Transplantation 109
Management of heart transplant candidates in the time of COVID-19 pandemic: Looking for answers 107
Evidence and current use of levosimendan in the treatment of heart failure: Filling the gap 105
Totale 16.591
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.990
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.990
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021248 0 0 0 0 0 0 0 0 0 0 0 248
2021/20221.601 66 51 108 214 132 70 41 121 65 149 322 262
2022/20232.110 192 269 109 256 182 189 55 114 379 86 193 86
2023/2024739 39 104 41 77 30 174 41 57 34 59 27 56
2024/20252.788 161 414 214 200 393 152 153 120 36 193 177 575
2025/20266.872 681 651 530 480 728 302 637 313 1.477 556 294 223
Totale 18.232